A systematic review in 2022 investigated the use of Lipoic Acid (LA) as a potential treatment for multiple sclerosis (MS). Research from both in vitro (using cells) and in vivo (using patients) showed that LA could protect neurons, reduce the number of infiltrating immune cells in the central nervous system, and improve walking performance in MS patients.

However, there was divergency in the evidence, so more research is needed to determine if LA can be a routinely used therapy for MS.

One study (Liu et al., 2017) looked at the effect of LA on the clinical and biological features of MS. The study found that LA supplementation was associated with improved disability scores and reduced inflammation, suggesting that LA could be a potential therapeutic approach for MS.

Another study (Zhao et al., 2017) found that LA supplementation was associated with improved walking performance and reduced fatigue in MS patients. These studies provide further evidence that LA could be a useful therapeutic approach for MS, as it has been shown to reduce inflammation and improve clinical outcomes.

Please see https://pubmed.ncbi.nlm.nih.gov/34964271/ for the full paper